Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
888 studies found for:    IL13
Show Display Options
RSS Create an RSS feed from your search for:
IL13
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Terminated An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-grade Glioma
Conditions: Brain Neoplasm;   Glioma
Intervention: Drug: IL13-PE38QQR
2 Withdrawn Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma
Condition: Recurrent Malignant Glioma
Intervention: Drug: IL13-PE38QQR
3 Not yet recruiting Validation of an Allergic Rhinitis Control Test in Teenagers
Condition: Allergic Rhinitis
Intervention: Other: Self questionnaire for allergic rhinitis control
4 Completed Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma
Conditions: Malignant Glioma;   Glioblastoma Multiforme;   Anaplastic Astrocytoma;   Mixed Oligoastrocytoma
Interventions: Drug: IL13-PE38QQR;   Procedure: targeted fusion protein therapy;   Procedure: surgery
5 Completed Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma
Conditions: Malignant Glioma;   Glioblastoma Multiforme;   Anaplastic Astrocytoma;   Mixed Oligoastrocytoma
Interventions: Drug: IL13-PE38QQR;   Procedure: targeted fusion protein therapy;   Procedure: surgery
6 Terminated Possible New Therapy for Advanced Cancer
Condition: Adrenocortical Carcinoma
Intervention: Drug: IL-13-PE
7 Completed Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma
Conditions: Malignant Glioma;   Glioblastoma Multiforme;   Anaplastic Astrocytoma;   Anaplastic Oligodendroglioma;   Mixed Oligoastrocytoma
Interventions: Drug: IL13-PE38QQR;   Procedure: targeted fusion protein therapy;   Procedure: surgery
8 Completed Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients
Conditions: Malignant Glioma;   Glioblastoma Multiforme;   Anaplastic Astrocytoma;   Mixed Oligoastrocytoma;   Malignant Astrocytoma
Interventions: Drug: IL13-PE38QQR;   Procedure: targeted fusion protein therapy;   Procedure: surgery
9 Withdrawn Immunotoxin Therapy in Treating Children With Recurrent Malignant Gliomas
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: cintredekin besudotox;   Procedure: conventional surgery
10 Completed IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma
Conditions: Glioblastoma Multiforme;   Anaplastic Astrocytoma;   Oligoastrocytoma
Interventions: Drug: IL13-PE38QQR;   Procedure: Surgery for placement;   Procedure: Radiation therapy;   Drug: Temozolomide with radiation therapy
11 Completed The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme
Condition: Glioblastoma Multiforme
Interventions: Drug: IL13-PE38QQR;   Procedure: surgery and catheter placement (2 procedures);   Drug: prolifespan 20 with carmustine implant (GLIADEL® Wafer);   Procedure: surgery and wafer placement (1 procedure)
12 Completed Sensitivity and Specificity of Nasal Provocation Test in Allergic Rhinitis to House Dust Mites
Condition: Allergic Rhinitis
Intervention: Other: Nasal provocation test
13 Completed Prospective Observational Study for Determination of Minimal Clinically Important Difference of Allergic Rhinitis Symptoms Due to Grass Pollen (Equinoxe 2)
Condition: Allergic Rhinitis Due to Grass Pollen
Intervention: Other: Allergic rhinitis
14 Completed Study to Investigate Effects of CAL-263 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber
Condition: Allergic Rhinitis
Interventions: Drug: CAL-263;   Drug: Placebo
15 Completed Open Study to Evaluate the Safety of Levocetirizine in Young Children (2 - 6 Years) Suffering From Allergic Rhinitis
Condition: Allergic Rhinitis
Intervention: Drug: Levocetirizine oral solution
16 Completed Sunovion Growth Study Pediatric Subjects With Mild Asthma & Allergic Rhinitis
Conditions: Asthma;   Allergic Rhinitis
Interventions: Drug: Alvesco/Omnaris, QVAR/Beconase, Placebo/Placebo;   Drug: Alvesco/Omnaris, Placebo/Placebo, QVAR/Beconase;   Drug: QVAR/Beconase, Alvesco/Omnaris, Placebo/Placebo;   Drug: QVAR/Beconase, Placebo/Placebo, Alvesco/Omnaris;   Drug: Placebo/Placebo, Alvesco/Omnaris, QVAR/Beconase;   Drug: Placebo/Placebo, QVAR/Beconase, Alvesco/Omnaris
17 Completed Comparison of Effectiveness and Safety of Sublingual Immunotherapy in Children With Allergic Rhinitis
Condition: Allergic Rhinitis
Interventions: Biological: sublingual allergen extract;   Biological: placebo
18 Completed Anti-inflammatory H1 Antihistamines Allergic Rhinitis
Condition: Allergic Rhinitis
Interventions: Drug: Levocetirizine;   Drug: Desloratadine
19 Completed
Has Results
Herbal Treatment for Perennial Allergic Rhinitis
Condition: Perennial Allergic Rhinitis
Interventions: Drug: Shi-Bi-Lin;   Other: Placebo
20 Completed The Effect Of PF-03654764 +/- Allegra On Symptoms Of Allergic Rhinitis
Condition: Allergic Rhinitis
Interventions: Drug: PF-03654764;   Drug: Allegra;   Drug: Allegra-D;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.